CA2418162A1 - Use of il-8 receptor antagonists in the treatment of virus infections - Google Patents

Use of il-8 receptor antagonists in the treatment of virus infections Download PDF

Info

Publication number
CA2418162A1
CA2418162A1 CA002418162A CA2418162A CA2418162A1 CA 2418162 A1 CA2418162 A1 CA 2418162A1 CA 002418162 A CA002418162 A CA 002418162A CA 2418162 A CA2418162 A CA 2418162A CA 2418162 A1 CA2418162 A1 CA 2418162A1
Authority
CA
Canada
Prior art keywords
viral infection
human
respiratory viral
therapeutic agent
respiratory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002418162A
Other languages
English (en)
French (fr)
Inventor
Susan B. Dillon
Ruth Tal-Singer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2418162A1 publication Critical patent/CA2418162A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002418162A 2000-07-18 2001-07-16 Use of il-8 receptor antagonists in the treatment of virus infections Abandoned CA2418162A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21905300P 2000-07-18 2000-07-18
US60/219,053 2000-07-18
PCT/US2001/022328 WO2002005814A1 (en) 2000-07-18 2001-07-16 Use of il-8 receptor antagonists in the treatment of virus infections

Publications (1)

Publication Number Publication Date
CA2418162A1 true CA2418162A1 (en) 2002-01-24

Family

ID=22817645

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002418162A Abandoned CA2418162A1 (en) 2000-07-18 2001-07-16 Use of il-8 receptor antagonists in the treatment of virus infections

Country Status (17)

Country Link
EP (1) EP1307190A4 (no)
JP (1) JP2004509852A (no)
KR (1) KR20030019587A (no)
CN (1) CN1449285A (no)
AR (1) AR033830A1 (no)
AU (1) AU2001273497A1 (no)
BR (1) BR0112603A (no)
CA (1) CA2418162A1 (no)
CZ (1) CZ2003132A3 (no)
HU (1) HUP0300754A3 (no)
IL (1) IL153921A0 (no)
MX (1) MXPA03000500A (no)
NO (1) NO20030201L (no)
NZ (1) NZ523659A (no)
PL (1) PL365886A1 (no)
WO (1) WO2002005814A1 (no)
ZA (1) ZA200300474B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006017505A2 (en) * 2004-08-04 2006-02-16 Schering Corporation Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
KR20170003673A (ko) * 2014-05-12 2017-01-09 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 감염성 질환을 치료하기 위한 다니릭신을 포함하는 약제 조성물
EP3884932A1 (en) * 2020-03-26 2021-09-29 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of covid-19
EP4008325A1 (en) * 2020-12-02 2022-06-08 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of covid-19
EP4125848A1 (en) * 2020-03-26 2023-02-08 Dompe' Farmaceutici SpA Cxcl8 inhibitors for use in the treatment of covid-19

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547979A (en) * 1992-03-30 1996-08-20 Smithkline Beecham TNF inhibition
WO1996005836A2 (en) * 1994-08-25 1996-02-29 Medical University Of South Carolina Methods of treating cold symptoms using pentoxifylline
JPH11503110A (ja) * 1995-02-17 1999-03-23 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体拮抗剤
SE9802729D0 (sv) * 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
SE9802937D0 (sv) * 1998-09-01 1998-09-01 Astra Pharma Prod Novel compounds

Also Published As

Publication number Publication date
CN1449285A (zh) 2003-10-15
EP1307190A1 (en) 2003-05-07
NZ523659A (en) 2006-01-27
CZ2003132A3 (cs) 2003-09-17
EP1307190A4 (en) 2007-08-22
ZA200300474B (en) 2004-08-17
JP2004509852A (ja) 2004-04-02
HUP0300754A2 (hu) 2003-08-28
IL153921A0 (en) 2003-07-31
HUP0300754A3 (en) 2009-03-02
PL365886A1 (en) 2005-01-10
WO2002005814A1 (en) 2002-01-24
KR20030019587A (ko) 2003-03-06
MXPA03000500A (es) 2003-06-24
BR0112603A (pt) 2004-08-24
AR033830A1 (es) 2004-01-07
AU2001273497A1 (en) 2002-01-30
NO20030201L (no) 2003-03-17
NO20030201D0 (no) 2003-01-15

Similar Documents

Publication Publication Date Title
AU763573B2 (en) Thiadiazolyl urea or thiourea derivatives for antiviral treatment
JP2656938B2 (ja) ｄｓＲＮＡと逆転写酵素インヒビターを含んで成るＨＩＶ感染治療のための医薬組成物
EP0509019B1 (en) Treatment of human retroviral infections with 2',3'-dideoxyinosine
Perry et al. Didanosine: an update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease
US7863242B2 (en) Compositions for down-regulation of CCR5 expression and methods of use thereof
Johnson et al. Three-Drug Synergistic Inhibition of HIV-l Replication In Vitro by Zidovudine, Recombinant Soluble CD4, and Recombinant Interferon-alpha A
US6214881B1 (en) IL-8 receptor antagonists
WO2010031832A2 (en) Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
WO1994004145A1 (en) Treatment of human viral infections
US20040038854A1 (en) Use of il-8 receptor antagonists in the treatment of virus infections
AU763431B2 (en) Viral treatment
Fraternale et al. Macrophage protection by addition of glutathione (GSH)-loaded erythrocytes to AZT and DDI in a murine AIDS model
CA2418162A1 (en) Use of il-8 receptor antagonists in the treatment of virus infections
US20040022762A1 (en) Use of il-8 protein modulators in the treatment of viral infections
EP1631559A2 (en) Il-8 receptor antagonists
EP1180028B1 (en) Il-8 receptor antagonists
AU5616100A (en) Il-8 receptor antagonists
US6248785B1 (en) IL-8 receptor antagonists
JPH01132526A (ja) 薬剤組成物
JP2004083576A (ja) Ｈｉｖ感受性株に対して活性をもち、ヌクレオシド系ならびに非ヌクレオシド系の逆転写酵素阻害剤、およびプロテアーゼ阻害剤に対し抵抗性のｈｉｖ株に対して活性をもつ抗レトロウイルス治療薬を得るための、クロロキン、ヒドロキシクロロキン、および４アミノ−キノリン酸誘導体の使用
AU767000B2 (en) IL-8 receptor antagonists
WO1989011860A1 (en) Combinations of soluble t4 proteins and anti-retroviral agents and methods for treating or preventing aids, arc and hiv infection
Foxworth Toxicities of antimicrobial agents used in the intensive care arena
JPH07508998A (ja) 抗ウイルス剤の組み合わせ
MXPA01009889A (en) Thiadiazolyl urea or thiourea derivatives for antiviral treatment

Legal Events

Date Code Title Description
FZDE Discontinued